Sökning: WFRF:(Koopman Miriam) > Reporting of patien...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04524naa a2200457 4500 | |
001 | oai:DiVA.org:uu-359368 | |
003 | SwePub | |
008 | 180904s2018 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3593682 URI |
024 | 7 | a https://doi.org/10.1016/j.ejca.2018.03.0262 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a for2 swepub-publicationtype |
100 | 1 | a Goey, Kaitlyn K. H.u Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands4 aut |
245 | 1 0 | a Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer :b A systematic review |
264 | 1 | b Elsevier BV,c 2018 |
338 | a print2 rdacarrier | |
520 | a Background: Patient characteristics and stratification factors are important factors influencing trial outcomes. Uniform reporting on these parameters would facilitate cross-study comparisons and extrapolation of trial results to clinical practice. In 2007, standardisation on patient characteristics reporting and stratification in metastatic colorectal cancer (mCRC) trials was proposed. We investigated the reporting of prognostic factors and implementation of this proposal in mCRC trials published from 2005 to 2016.Methods: We searched PubMed and Embase (January 2005 – June 2016) for first-line phase 3 mCRC trials. Patient characteristics reporting and use of stratification factors were extracted and analysed for adherence to the proposal from 2007.Results: Sixty-seven trials (35,315 patients) were identified, reporting 48 different patient characteristics (median: 9 [range: 5–18] per study). Age, gender, performance status (PS), primary tumour site and adjuvant chemotherapy were frequently reported (87%–100%), in contrast to laboratory values, such as alkaline phosphatase, lactate dehydrogenase and white blood cell count (10%–25%). We identified 29 different stratification factors (median: 3 [range: 1–9] per study). The most common strata were PS and treatment centre (>60%). A median of 8/12 (range: 4–11) of the proposed parameters was reported. Although the percentage of studies reporting each factor slightly increased over time, there was no significant correlation between publication year and adherence to the proposal from 2007.Conclusions: We observed persistent heterogeneity in the reporting of patient characteristics and use of stratification factors in first-line mCRC trials. The proposal from 2007 has not led to increased uniformity of patient characteristics reporting and use of stratification over time. There is an urgent need to address this issue to improve the interpretation of trial results. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a Colorectal cancer | |
653 | a Metastatic disease | |
653 | a Patient characteristics | |
653 | a Prognosis | |
653 | a Stratification | |
653 | a Systematic review | |
653 | a Clinical trials | |
700 | 1 | a Mahmoud, Remiu Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands4 aut |
700 | 1 | a Sørbye, Halfdanu Haukeland Hosp, Dept Oncol, Bergen, Norway; Haukeland Hosp, Dept Clin Sci, Bergen, Norway4 aut |
700 | 1 | a Glimelius, Bengtu Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)bengglim |
700 | 1 | a Köhne, Claus-Henningu Klinikum Oldenburg, Univ Clin Internal Med Oncol & Hematol, Oldenburg, Germany4 aut |
700 | 1 | a Sargent, Daniel J.u Mayo Clin, Ctr Canc, Div Biomed Stat & Informat, Rochester, MN USA4 aut |
700 | 1 | a Punt, Cornelis J. A.u Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, Amsterdam, Netherlands4 aut |
700 | 1 | a van Oijen, Martijn G. H.u Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, Amsterdam, Netherlands4 aut |
700 | 1 | a Koopman, Miriamu Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands4 aut |
710 | 2 | a Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlandsb Haukeland Hosp, Dept Oncol, Bergen, Norway; Haukeland Hosp, Dept Clin Sci, Bergen, Norway4 org |
773 | 0 | t European Journal of Cancerd : Elsevier BVg 96, s. 115-124q 96<115-124x 0959-8049x 1879-0852 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-359368 |
856 | 4 8 | u https://doi.org/10.1016/j.ejca.2018.03.026 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy